Astragaloside II is an orally active Cycloartane-type triterpene glycoside extracted from *Astragalus membranaceus*. It is used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis. It functions by inhibiting autophagy, decreasing pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, and p-IκB, and increasing superoxide dismutase (SOD). It also regulates immunity and reduces inflammatory responses.
- Promotes cell viability of rat primary osteoblasts.
- Enhances proliferation of primary splenocytes.
- Sensitizes cells to 5-fluorouracil-induced cell death.
- Inhibits levels of HIF-α, p-p65, and p-IκB, demonstrating an anti-inflammatory effect.
- Alleviates symptoms of DSS-induced ulcerative colitis in mice.
- Reduces DAI score and prevents body weight loss in vivo.
- Increases colon length and superoxide dismutase in colon tissues.